<DOC>
	<DOCNO>NCT01054443</DOCNO>
	<brief_summary>This Phase 2 , multicenter , randomize , double-blind , placebo-controlled , dose-ranging , parallel-group study evaluate efficacy , safety , pharmacokinetics , pharmacodynamics S-888711 treatment subject immune thrombocytopenia . Eligible subject randomize one four treatment group receive S-888711 0.5 mg , 0.75 mg , 1.0 mg placebo .</brief_summary>
	<brief_title>A Study Investigate Efficacy Safety S-888711 Tablets Administered Adult Subjects With Immune Thrombocytopenia ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>A sign date write informed consent Males females ≥ 18 year age All subject must agree use barrier contraception Diagnosis ITP Subjects &gt; 60 year must diagnostic bone marrow aspiration Relapsed persistent chronic ITP status , without prior splenectomy ( exception : Hungary splenectomized subject enrol ) , fail least 1 prior ITP therapy ( exclude TPO agonist ) platelet count &lt; 30,000/μL take medication &lt; 50,000/μL despite concomitant steroid ITP therapy , danazol immunosuppressive drug Subjects receive steroid therapy must stable dose PT APTT within 20 % upper limit normal Subjects receive stable dosage cyclosporine A , mycophenolate mofetil , azathioprine , danazol allow . The dosages medication must stable least 4 week prior Visit 1 ( Day 1 ) History clinically important hemorrhagic clot disorder Females pregnant , lactating , take oral contraceptive History alcohol/drug abuse dependence within 1 year Use follow drug treatment prior Visit 1 ( Day 1 ) : Within 12 week alemtuzumab , multidrug systemic chemotherapy , stem cell therapy ; Within 8 week rituximab Within 2 week platelet transfusion plasmapheresis treatment Within 4 week use antiplatelet anticoagulant drug Within 1 week Rho ( D ) immune globulin intravenous immunoglobulin History clinically significant cardiovascular thromboembolic disease within 26 week prior Screening Splenectomy within 4 week prior Screening Clinically significant laboratory abnormality Hemoglobin &lt; 10.0 g/dL men woman , clearly relate ITP Absolute neutrophil count &lt; 1000/mm3 Abnormal peripheral blood smear Total bilirubin &gt; 1.5 x upper limit normal Alanine aminotransferase ( ALT ) &gt; 1.5 x upper limit normal Aspartate aminotransferase ( AST ) &gt; 1.5 x upper limit normal Creatinine &gt; 1.5 x upper limit normal Human immunodeficiency virus ( HIV ) positive Hepatitis A IgM antibody ( IgM HAV ) positive , hepatitis B surface antigen ( HbsAg ) hepatitis C antibody ( HCV ) positive Thyroid stimulate hormone ( TSH ) &gt; 1.5 x upper limit normal Free thyroxine ( T4 ) &gt; 1.5 x upper limit normal Exposure previous TPO mimetics/agonists ( e.g. , eltrombopag , romiplostim , E5501 [ AKR501 ] LGD4665 ) within 4 week prior Screening Subjects unresponsive previous TPO mimetics/agonists ( e.g. , eltrombopag , romiplostim , E5501 [ AKR501 ] LGD4665 ) Exposure investigative medication within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Immune Thrombocytopenia ( ITP )</keyword>
	<keyword>Low Platelet Count</keyword>
	<keyword>Thrombocytopaenia</keyword>
	<keyword>S-888711</keyword>
	<keyword>Splenectomy</keyword>
	<keyword>Thrombopoiesis</keyword>
	<keyword>Hematologic Disease</keyword>
	<keyword>Auto-immune thrombocytopenic Purpura</keyword>
	<keyword>Relapsed Persistent Chronic ITP</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Thrombotic Thrombocytopenic Purpura ( TTP )</keyword>
</DOC>